“CORI on Tour” will highlight the latest advancements in robotics-assisted surgery for hip and knee joint replacement Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a months-long roadshow across central Europe to promote its CORI Surgical System – an advanced robotics-assisted surgical platform for total knee and hip joint replacement procedures. The tou...
Smith & Nephew plc (NYSE:SNN ) Q1 2025 Results Conference Call April 30, 2025 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Julien Dormois - Jefferies Jack Reynolds-Clark - RBC Capital Markets Lisa Clive - Bernstein Hassan Al-Wakeel - Barclays Kane Slutzkin - Deutsche Bank D...
Smith & Nephew PLC (LSE:SN) rose as much as 7% in afternoon trading on Wednesday after the medical technology group reported stronger-than-expected revenue growth in the first quarter of 2025. The London-listed company posted underlying revenue growth of 3.1% in the three months to March, ahead market consensus of 1.9%.
Smith & Nephew PLC (LSE:SN) shares rose over 5% to top the early FTSE 100 leaderboard on Wednesday after the knee and hip replacer maintained its full-year 2025 guidance after seeing growth of 3.1% in underlying revenue for the first quarter. The performance was supported by recent product launches and continued operational improvements across its business lines, with total reported revenue up ...
Smith & Nephew is undergoing a turnaround under CEO Deepak Nath, focusing on margin expansion and growth through surgical robotics and regenerative technologies. Despite trading at a discount to peers, the company shows visible margin improvement, offering a compelling value proposition for investors. The base case projects 35% upside by 2025 with a 20% trading margin, while the bull case sugge...
Global financial markets are in turmoil this morning after the US President announced sweeping tariffs on several countries in a push to lower the nation's trade deficit. Trump's new tariffs are particularly expected to hurt European companies with significant revenue exposure to the United States.
Shares in Smith & Nephew PLC (LSE:SN) fell 2% after UBS downgraded stock in the med-tech firm to 'neutral' from 'buy' on valuation grounds. The price target remains at £12.50.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.